Santarus Inc (SNTS)

[surf1944]

7:01AM Santarus announces presentation of SAN-300 Phase I data at 2013 American College of Rheumatology Annual Meeting; plan to initiate Phase IIa clinical study in patients with rheumatoid arthritis by year-end 2013 (SNTS) 24.60 : Co announced that data from its Phase I clinical study with its investigational drug SAN-300, a novel antibody that inhibits very late antigen-1 (VLA-1; a1 1 integrin), will be featured in a poster presentation at the 2013 American College of Rheumatology. Based on the Phase I study results, Santarus is preparing to initiate a multicenter, randomized, placebo-controlled, multiple ascending dose, Phase IIa clinical study with subcutaneous administration of SAN-300 in patients with active rheumatoid arthritis. The co expects to initiate the Phase IIa study in the fourth quarter of 2013.